AS
ASTE.NS
—
NSE (India)
Agricultural Chemicals
Astec Lifesciences Ltd
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-11,5 %
ROE
-20,7 %
Net margin
-18,1 %
Debt / equity
1,15
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$51,40
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Astec Lifesciences Ltd is a company engaged in the production and sale of agricultural chemicals, primarily serving the Basic Materials sector.
Business. Astec Lifesciences Ltd (ASTE.NS) is an Indian company operating in the agricultural chemicals industry within the broader chemicals sector. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. As specific segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the agricultural chemicals market.
Classification92 %
SectorBasic Materials
Business sectorChemicals
IndustryAgricultural Chemicals
ActivityChemicals
Generated · model-assisted
Sell-side consensus
SELL1 analysts
0 buy0 hold1 sell
Avg 12m price target600,00
Analyst recommendations
1 analysts · consensus SellBuy0
Hold0
Sell1
12-month price target
600,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Sell
1 analysts · indicative
Ownership→
Dimensional Fund Advisors, L.P.
largest disclosed fund holder
Profitability→
-20,7 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ASTE.NS. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Astec Lifesciences Ltd (ASTE.NS) is an Indian company operating in the agricultural chemicals industry within the broader chemicals sector. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. As specific segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the agricultural chemicals market.
Classification92 %
SectorBasic Materials
Business sectorChemicals
IndustryAgricultural Chemicals
ActivityChemicals
AI synthesis
GENERATEDAstec Lifesciences Ltd exhibits a capital structure with a debt-to-equity ratio of 1.15, indicating a moderate reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.89 and negative free cash flow of -414.9 million INR. The company's cash and equivalents amount to 22.0 million INR, which is significantly lower than its long-term debt of 4,489.3 million INR.
Profitability metrics for Astec Lifesciences Ltd are negative, with a return on equity of -20.72% and a return on assets of -8.59%. These figures are below the industry norms for Agricultural Chemicals, suggesting underperformance in generating returns for shareholders and asset utilization.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks.
Astec Lifesciences Ltd is currently experiencing a decline in its financial performance, with a net loss of 809.2 million INR and an operating loss of 515.4 million INR. The outlook for the next fiscal year is uncertain, with no clear indicators of improvement in the provided data.
The company faces significant liquidity and solvency risks, as indicated by its negative operating cash flow of -807.1 million INR and a net loss. The risk assessment highlights a medium liquidity risk and a low dilution risk, with no immediate signs of equity dilution.
Recent events and filings do not provide specific details on new developments or strategic initiatives for Astec Lifesciences Ltd. The company's financial statements and risk assessment suggest a need for strategic adjustments to improve its financial health and operational performance.
Key takeaways
- Astec Lifesciences Ltd is experiencing significant financial losses, with a net loss of 809.2 million INR and an operating loss of 515.4 million INR.
- The company's liquidity position is weak, with a current ratio of 0.89 and negative free cash flow.
- Profitability metrics are negative, with a return on equity of -20.72% and a return on assets of -8.59%.
- The company's capital structure is heavily reliant on debt, with a debt-to-equity ratio of 1.15.
- There is no clear indication of improvement in the company's financial performance for the next fiscal year.
- The company's revenue is concentrated in a single business segment, with no geographic diversification provided.
- **margin_outlook_rationale**: The company's gross margin is under pressure due to declining sales and rising costs.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$675,80
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$3.91B
Net cashⓘ
-$4.47B
Current ratioⓘ
0.9
Debt / equityⓘ
1.1
ROAⓘ
-8.6%
ROEⓘ
-20.7%
Cash conversionⓘ
100.0%
CapEx / revenueⓘ
-1.2%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures
Partners2
Sandvik ABSAND.STPartner90%Source ↗
WEIR GROUP INC.WEIR.LPartner90%Source ↗
Supply chain
Vendors → ASTE ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
12,60
Predicted surprise
+0,00
Beat probability
45 %
Analysts
1
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-15 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 12,60 |
| Revenue | —no estimate | —no estimate | 6,5B INR |
| Operating income | —no estimate | —no estimate | 565,0M INR |
Full-year consensus mean (period as reported by source) · consensus in INR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution1 analysts
Strong buy0
Buy0
Hold0
Sell1
Strong sell0
12-month price target$600,00 · Median $600,00
Low $600,00High $600,00
Operating income · consensus565,0M INR
EPS surprise
−392,1 %
reported vs consensus · miss
Revenue surprise
−30,9 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$600,00
Mean$600,00
Median$600,00
High$600,00
Spot$675,80
−11.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-11,5 %Bottom quartile
Net Margin-18,1 %Bottom quartile
ROE-20,7 %Bottom quartile
Capex / Rev-1,2 %Above P75
D/E1,15Bottom quartile
Cash Conv1,00Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net flat1 grants1 insiders
- Chief Executive Officer · Phantom Stock → Common StockAcquired 0grant · 2026-05-29
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- Astec Lifesciences Ltd Market data — financials · 2026-05-27
- Astec Lifesciences Ltd Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,02 %$77M
- Investment Managers · as of 2026-03-310,01 %$27M
- Funds · as of 2026-03-310,01 %$39M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$22M
- Institutional Investor · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2024-06-300,00 %$119M
- Investment Managers · as of 2026-03-310,00 %$6M
- Institutional Investor · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$31M
- Investment Managers · as of 2026-03-310,00 %$14M
- Investment Managers · as of 2026-03-310,00 %$47M
- Investment Managers · as of 2025-12-310,00 %$108M
- Investment Managers · as of 2026-03-310,00 %$21M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-12-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Jaco Van Der MerwePresident, Chief Executive Officer, Director
Insider activity
Mixed / flat0 buys · 0 sellsnet $015 insiders · last 365d
- Director · Common StockOther 390 · 2026-07-31
- Director · Common StockOther 15 · 2026-05-29
- Director · Common StockOther 6 · 2026-05-29
- VP, Chief Accounting Officer · Common StockOther 3 · 2026-05-29
- GC & CORPORATE SECRETARY · Common StockOther 19 · 2026-05-29
- Chief Financial Officer · Common StockOther 32 · 2026-05-29
- GROUP PRESIDENT · Common StockOther 20 · 2026-05-29
- Chief Executive Officer · Common StockOther 121 · 2026-05-29
- Director · Common StockOther 15 · 2026-05-29
- Director · Common StockOther 6 · 2026-05-29
- Director · Common StockOther 6 · 2026-05-29
- Director · Common StockOther 6 · 2026-05-29
- Director · Common StockOther 6 · 2026-05-29
- Director · Common StockOther 21 · 2026-05-29
- Director · Common StockOther 2 365 · 2026-04-27
- Director · Common StockOther 317 · 2026-04-27
- Director · Common StockOther 2 365 · 2026-04-27
- Director · Common StockOther 2 365 · 2026-04-27
- Director · Common StockOther 2 365 · 2026-04-27
- Director · Common StockOther 2 365 · 2026-04-27
- Director · Common StockOther 2 365 · 2026-04-27
- Director · Common StockOther 2 365 · 2026-04-27
- Director · Common StockOther 2 365 · 2026-04-27
- VP, Chief Accounting Officer · Common StockOther 3 · 2026-03-31
- Director · Common StockOther 9 · 2026-03-31
Short positioning
571.1Kshares short+4.2% vs prior
3.37days to cover
26.3%short of daily vol
465fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ASTE.NSCanonical
NSE (India) · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorPartners
Evidence & claims
From filings & derived data- Net income (YoY) (2025-12-31 vs 2024-12-31): 802.3%Derived (calculated)
- Net margin (FY 2025-12-31): 2.8%Derived (calculated)
- Gross margin (FY 2025-12-31): 26.5%Derived (calculated)
- Return on equity (FY 2025-12-31): 5.7%Derived (calculated)
- Return on assets (FY 2025-12-31): 2.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.49xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.01xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 98.5%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -20.7%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 6.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 794.7%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 784.2%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 14.1%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 204.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 167.0%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 184.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 13.0%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 8.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 6.9%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 31.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 68.9%Derived (calculated)
- Operating cash flow (annual): USD 61.4MSEC XBRL filing
- Revenue (annual): USD 1.41BSEC XBRL filing
- Pre-tax income (annual): USD 53.1MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-31 04:36 UTCFILINGMaterial 8-K
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-05-29 00:00 UTCINSIDER14 insider transactions — 2026-05 1 derivative
2026-05-29 00:00 UTCINSIDER14 insider transactions — 2026-05 1 derivative
2026-05-29INSIDERShannon Patrick S transacted 15 sh — Director
2026-05-29INSIDERWINFORD JAMES MURPHY JR transacted 6 sh — Director
2026-05-29INSIDERPUTNEY ROBERT GERALD transacted 3 sh — VP, Chief Accounting Officer
2026-05-29INSIDERGILBERT EDWARD TERRELL JR transacted 19 sh — GC & CORPORATE SECRETARY
2026-05-29INSIDERHarris Brian James transacted 32 sh — Chief Financial Officer
2026-05-29INSIDERNORRIS MICHAEL PAUL transacted 20 sh — GROUP PRESIDENT
2026-05-29INSIDERMerwe Jaco van der transacted 121 sh — Chief Executive Officer
2026-05-29INSIDERCook Tracey H transacted 15 sh — Director
2026-05-29INSIDERGliebe Mark Joseph transacted 6 sh — Director
2026-05-29INSIDERHOWELL MARY L transacted 6 sh — Director
2026-05-29INSIDERJain Nalin transacted 6 sh — Director
2026-05-29INSIDERKnoll Linda I. transacted 6 sh — Director
2026-05-29INSIDERJackson Jeffrey T transacted 21 sh — Director
2026-05-29INSIDERMerwe Jaco van der acquired 4 sh Phantom Stock — Chief Executive Officer
2026-04-27 00:00 UTCINSIDER9 insider transactions — 2026-04
2026-04-27 00:00 UTCINSIDER9 insider transactions — 2026-04
2026-04-27INSIDERShannon Patrick S transacted 2.4k sh — Director
2026-04-27INSIDERJackson Jeffrey T transacted 317 sh — Director
2026-04-27INSIDERJackson Jeffrey T transacted 2.4k sh — Director
2026-04-27INSIDERKnoll Linda I. transacted 2.4k sh — Director
2026-04-27INSIDERWINFORD JAMES MURPHY JR transacted 2.4k sh — Director
2026-04-27INSIDERCook Tracey H transacted 2.4k sh — Director
2026-04-27INSIDERGliebe Mark Joseph transacted 2.4k sh — Director
2026-04-27INSIDERHOWELL MARY L transacted 2.4k sh — Director
2026-04-27INSIDERJain Nalin transacted 2.4k sh — Director
2026-03-31 00:00 UTCINSIDER3 insider transactions — 2026-03
2026-03-31 00:00 UTCINSIDER3 insider transactions — 2026-03
2026-03-31INSIDERPUTNEY ROBERT GERALD transacted 3 sh — VP, Chief Accounting Officer
2026-03-31INSIDERGEHL WILLIAM D transacted 9 sh — Director
2026-03-31INSIDERGEHL WILLIAM D transacted 48 sh — Director
Showing the 40 most recent of 49 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage